These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24059236)

  • 21. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development.
    Fitzgerald MF; Fox JC
    Drug Discov Today; 2007 Jun; 12(11-12):479-86. PubMed ID: 17532533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemokine release by neutrophils in chronic obstructive pulmonary disease.
    Blidberg K; Palmberg L; Dahlén B; Lantz AS; Larsson K
    Innate Immun; 2012 Jun; 18(3):503-10. PubMed ID: 21997704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curcumin modulates the effect of histone modification on the expression of chemokines by type II alveolar epithelial cells in a rat COPD model.
    Gan L; Li C; Wang J; Guo X
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2765-2773. PubMed ID: 27853364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender differences in the T-cell profiles of the airways in COPD patients associated with clinical phenotypes.
    Forsslund H; Yang M; Mikko M; Karimi R; Nyrén S; Engvall B; Grunewald J; Merikallio H; Kaarteenaho R; Wahlström J; Wheelock ÅM; Sköld CM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():35-48. PubMed ID: 28053515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Handle with care: targeting neutrophils in chronic obstructive pulmonary disease and severe asthma?
    Beeh KM; Beier J
    Clin Exp Allergy; 2006 Feb; 36(2):142-57. PubMed ID: 16433851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutrophil chemokines in severe exacerbations of chronic obstructive pulmonary disease: fatal chemo-attraction?
    Saetta M; Baraldo S; Zuin R
    Am J Respir Crit Care Med; 2003 Oct; 168(8):911-3. PubMed ID: 14555454
    [No Abstract]   [Full Text] [Related]  

  • 27. Analysis of homing receptor expression on infiltrating leukocytes in disease states.
    Mariani M; Panina-Bordignon P
    J Immunol Methods; 2003 Feb; 273(1-2):103-14. PubMed ID: 12535801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD.
    Costa C; Traves SL; Tudhope SJ; Fenwick PS; Belchamber KB; Russell RE; Barnes PJ; Donnelly LE
    Eur Respir J; 2016 Apr; 47(4):1093-102. PubMed ID: 26965295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemokine receptors as specific anti-inflammatory targets in peripheral nerves.
    Ubogu EE
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):141-53. PubMed ID: 21476965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agents against cytokine synthesis or receptors.
    Yamagata T; Ichinose M
    Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components.
    Chen X; Oppenheim JJ; Howard OM
    Cell Mol Immunol; 2004 Oct; 1(5):336-42. PubMed ID: 16285892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-17A Is Elevated in End-Stage Chronic Obstructive Pulmonary Disease and Contributes to Cigarette Smoke-induced Lymphoid Neogenesis.
    Roos AB; Sandén C; Mori M; Bjermer L; Stampfli MR; Erjefält JS
    Am J Respir Crit Care Med; 2015 Jun; 191(11):1232-41. PubMed ID: 25844618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease.
    Jiang Z; Zhu L
    Pulm Pharmacol Ther; 2016 Apr; 37():1-8. PubMed ID: 26805715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of new drugs for COPD.
    Barnes PJ
    Curr Med Chem; 2013; 20(12):1531-40. PubMed ID: 22963554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotactic mediators of Th1 T-cell trafficking in smokers and COPD patients.
    Brozyna S; Ahern J; Hodge G; Nairn J; Holmes M; Reynolds PN; Hodge S
    COPD; 2009 Feb; 6(1):4-16. PubMed ID: 19229703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting chemokines: Pathogens can, why can't we?
    Proudfoot AE; Bonvin P; Power CA
    Cytokine; 2015 Aug; 74(2):259-67. PubMed ID: 25753743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging drugs for the treatment of chronic obstructive pulmonary disease.
    Malhotra S; Man SF; Sin DD
    Expert Opin Emerg Drugs; 2006 May; 11(2):275-91. PubMed ID: 16634702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemokine blockers--therapeutics in the making?
    Wells TN; Power CA; Shaw JP; Proudfoot AE
    Trends Pharmacol Sci; 2006 Jan; 27(1):41-7. PubMed ID: 16310864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice.
    Bracke KR; D'hulst AI; Maes T; Moerloose KB; Demedts IK; Lebecque S; Joos GF; Brusselle GG
    J Immunol; 2006 Oct; 177(7):4350-9. PubMed ID: 16982869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.